**Abstract**

In recent studies we have shown that the tryptophan (TRP) depletion model of depression previously validated in male rats is paroxetine-resistant in females (Franklin et al. 2015). In this model, we found that secretion of the mineralocorticoid hormone aldosterone increased after 4 days of TRP depletion and surprisingly prior to corticosterone enhancement. The study aim was to investigate the effects of mineralocorticoid receptor (MR) blockade on depression-like behaviour induced by TRP depletion.

Female rats were fed a control (0.2% of TRP) or low TRP diet (0.04% of TRP) for 14 days. They were simultaneously treated with the MR antagonist spironolactone (1.2 mg/rat/day) or placebo via matrix-driven delivery pellets (Innovative Research of America, USA) for 14 days. Rats were tested in the Forced Swim Test (FST) on treatment day 14. Animals were sacrificed by decapitation on day 15.

Two-way ANOVA showed that TRP depletion resulted in an increased immobility time in the FST. Further analysis showed that TRP-depleted rats treated with spironolactone but with placebo spent a significantly shorter time immobile compared to controls. Rats exposed to TRP depletion exhibited significantly higher serum concentrations of aldosterone and corticosterone, which were slightly modified by spironolactone treatment. TRP depletion significantly enhanced serum interleukin-6 as well as gene expression of orexin A, a neuropeptide related to ghrelin, which has been shown to be altered in patients with treatment-resistant depression.

Findings show that treatment of rats with the MR antagonist spironolactone results in a mild improvement of TRP depletion-induced depression-like behaviour. Blockade of aldosterone action could represent a target for new antidepressant treatment.
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